Navigation Links
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Date:6/3/2008

y factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts: Media:

Corporate: GendeLLindheim BioCom Partners

Steven D. Rubin Barbara Lindheim

305 575-6015 212 918-4650


'/>"/>
SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
2. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
3. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
4. Newly Approved HIV Drug Shows Great Promise
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... a Little Help ... Series,PSA Expands Partnership Between VH1 and Nothing But Nets to Prevent Malaria ... in Africa, ... very serious issue in a new Public,Service Announcement (PSA) created by VH1 for Nothing But ...
... Immtech Pharmaceuticals,Inc. (Amex: IMM ) today announced ... consortium led by the University of North Carolina ... Bill & Melinda Gates Foundation,(the "Gates Foundation"), to ... leishmania. This grant is part of the $22.6,million ...
Cached Medicine Technology:'Best Week Ever' for Nothing But Nets 2'Best Week Ever' for Nothing But Nets 3Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 2Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 3
(Date:4/20/2014)... of cell in the lining of the bladder is ... to researchers at the Stanford University School of Medicine. ... to pinpoint the normal cell type that can give ... to show that most bladder cancers and their associated ... why many human bladder cancers recur after therapy. , ...
(Date:4/18/2014)... medical-testing device is being prepped to enter the ... diagnosis of certain diseases in remote areas, thanks ... of investigations aboard the International Space Station on ... space-tested concept of capillary flow to diagnose infectious ... Kelso, Ph.D., a researcher at Northwestern University in ...
(Date:4/18/2014)... neuroscientists have made a discovery that turns 160 years ... insulating material long known to be essential for the ... cells, is not as ubiquitous as thought, according to ... the Harvard Stem Cell Institute (HSCI) and the University,s ... with Professor Jeff Lichtman, of Harvard,s Department of Molecular ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2
... study raises the question, do barriers to health ... risk of tuberculosis? The study, published in the ... Diseases and now available online, suggests that ... seeking care than documented immigrants or U.S.-born patients, ...
... CHICAGO October 29, 2008 Shire plc (LSE: ... announced results from a 13-hour analog classroom study in ... Deficit Hyperactivity Disorder (ADHD). In this study, researchers ... time point measured (1.5 hours) through the last time ...
... 29 Trust for America,s,Health (TFAH) released ... Why Emerging,Infectious Diseases Are a Threat to ... die annually from newly emerging and re-emerging,infectious ... during a,severe flu pandemic or yet-unknown disease ...
... ARE PASSIVE AND INEFFECTIVE, NEW YORK, Oct. ... should be using the most effective tool,to protect ... Betsy,McCaughey, Ph.D., Chairman of the not-for-profit Committee to ... physicians., Today, RID is releasing a new ...
... drug resistance and climate change as culprits , , WEDNESDAY, ... die each year from infectious diseases, and that number ... That dire news was delivered in a report, ... Threat to America , released Wednesday by the Trust ...
... Foundation,Radiology Group (FRG) signed a multi-year contract with ... of diagnostic,imaging services effective December 31, 2008., ... Pennsylvania,and services multiple counties in north central Pennsylvania ... wide range of primary and,secondary health care services ...
Cached Medicine News:Health News:Health-care barriers for undocumented immigrants: Raising tuberculosis risk? 2Health News:VYVANSE provided behavior, inattention and math test score improvements in children with ADHD 2Health News:VYVANSE provided behavior, inattention and math test score improvements in children with ADHD 3Health News:New Report Finds Rising Risk of Infectious Diseases in America 2Health News:New Report Finds Rising Risk of Infectious Diseases in America 3Health News:New Report Finds Rising Risk of Infectious Diseases in America 4Health News:New Report Finds Rising Risk of Infectious Diseases in America 5Health News:New Report Finds Rising Risk of Infectious Diseases in America 6Health News:Professional Sports Teams Should Use MRSA Screening and Other Aggressive Methods to Prevent Staph Infections 2Health News:Threat From Infectious Diseases Growing 2Health News:Threat From Infectious Diseases Growing 3Health News:Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: